Loading company…
Ternary Therapeutics uses computational design to develop molecular glue degraders and activators for drug discovery.
Founded in 2024 and based in London, Ternary Therapeutics develops molecular glue degraders and activators using a computational design platform. Its work focuses on identifying protein surface sites for therapeutic design and serves pharmaceutical and biotechnology organizations. In March 2026, the company raised GBP 3.6 million in Seed funding led by Daphni, with participation from Future Planet Capital, Pace Ventures Enigma and i&i Bio. It plans to expand its computational and laboratory teams and advance lead programmes toward preclinical development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in